Antisense Therapeutics Price To Sales vs. Cash And Equivalents
| ATHJF Stock | USD 0.04 0.00 0.00% |
For Antisense Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Antisense Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Antisense Therapeutics Limited utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Antisense Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Antisense Therapeutics Limited over time as well as its relative position and ranking within its peers.
Antisense |
Antisense Therapeutics Cash And Equivalents vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Antisense Therapeutics's current stock value. Our valuation model uses many indicators to compare Antisense Therapeutics value to that of its competitors to determine the firm's financial worth. Antisense Therapeutics Limited is rated third in price to sales category among its peers. It also is rated third in cash and equivalents category among its peers creating about 786,175 of Cash And Equivalents per Price To Sales. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Antisense Therapeutics' earnings, one of the primary drivers of an investment's value.Antisense Cash And Equivalents vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Antisense Therapeutics |
| = | 24.46 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Antisense Therapeutics |
| = | 19.23 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Antisense Cash And Equivalents Comparison
Antisense Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Antisense Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Antisense Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Antisense Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Antisense Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Antisense Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia. Antisense Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Antisense Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Antisense Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Antisense Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Antisense Therapeutics' important profitability drivers and their relationship over time.
Use Antisense Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Antisense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Antisense Therapeutics will appreciate offsetting losses from the drop in the long position's value.Antisense Therapeutics Pair Trading
Antisense Therapeutics Limited Pair Trading Analysis
The ability to find closely correlated positions to Antisense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Antisense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Antisense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Antisense Therapeutics Limited to buy it.
The correlation of Antisense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Antisense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Antisense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Antisense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Antisense Therapeutics position
In addition to having Antisense Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Energy Funds Thematic Idea Now
Energy Funds
Funds or Etfs investing in energy sector, natural resources, and ecology. The Energy Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Energy Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Antisense Pink Sheet
To fully project Antisense Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Antisense Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Antisense Therapeutics' income statement, its balance sheet, and the statement of cash flows.